SignalFDA/Bio
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
Epcoritamab plus R-CHOP shows statistically significant progression-free survival improvement in newly diagnosed DLBCL.
Context
What happened: Genmab and AbbVie reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients with an IPI score of 2 to 5.
Key numbers: Risk of disease progression or death reduced by 51% (HR 0.49 [95% CI 0.36,
Why it matters: The companies said this is the first Phase 3 study of a bispecific antibody combination to show a statistically significant PFS improvement in frontline DLBCL, and they will engage global regulatory authorities based on the topline results.
What changed
Genmab and AbbVie reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients with an IPI score of 2 to 5.
Why it matters
The companies said this is the first Phase 3 study of a bispecific antibody combination to show a statistically significant PFS improvement in frontline DLBCL, and they will engage global regulatory authorities based on the topline results.